TSBX חוב לטווח קצר של החברה Turnstone Biologics Corp.

Turnstone Biologics (TSBX) develops personalized vaccines and TIL-based therapies, leveraging patent protection and FDA data. The business expands through partnerships with scientific centers to develop immunotherapy. High R&D costs and strict regulatory oversight create significant barriers to entry for competitors. This price chart confirms these data, with the indicator standing at 0.00.

For Turnstone Biologics (TSBX), whose operations are strictly regulated by FDA standards, liquidity management is critical when financing clinical trials. This short-term debt burden metric aggregates all credit obligations maturing within twelve months, allowing for an assessment of working capital deficit risks. Monitoring this metric helps investors timely identify a dangerous increase in borrowing that could lead to a price collapse during a shift in the market cycle.